BioSpace News Archive

QIAGEN welcomes the publication of a new, systematic review highlighting the unique value of its proprietary tuberculosis testing technology.

Agile Therapeutics, Inc., a women’s healthcare company, announced that Twirla will become available through FPA Women’s Health.

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced that it intends to offer and sell shares of its common stock and pre-funded warrants in an underwritten public offering.

Arvinas, Inc. announced that Timothy Shannon, M.D., current Chairperson and a member of the company’s Board of Directors since 2013, has stepped down from this role.

PTC Therapeutics, Inc. announced that on June 12, 2023, the company approved non-statutory stock options to purchase an aggregate of 11,260 shares of its common stock and 17,660 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 23 new employees.

Clene Inc. and its wholly owned subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, reported new data demonstrating a statistically significant reduction of plasma neurofilament light chain levels for CNM-Au8® treated participants compared to placebo after 24 weeks of treatment in the double-blind, placebo-controlled period of the HEALEY ALS Platform Trial.

SQZ Biotechnologies Company, focused on unlocking the full potential of cell therapies, announced that its Board of Directors has approved a 1-for-10 reverse stock split of its common stock, par value $0.001 per share, that is expected to become effective on Thursday, July 6, 2023 at 5:00 p.m. Eastern Time.

Hepion Pharmaceuticals, Inc. announced that two abstracts have been accepted for poster presentations at the European Association for the Study of the Liver International Liver Congress™ 2023 taking place June 21 - 24, 2023 in Vienna, Austria and digitally.

Azitra, Inc. announced the pricing of its initial public offering of 1,500,000 shares of common stock at a public offering price of $5.00 per share, for aggregate gross proceeds of $7,500,000 prior to deducting underwriting discounts and other offering expenses.

Reata Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration accepted for filing the Prior Approval Supplement to update the drug substance specification for SKYCLARYS®.